Clinical Impact of New Viral Hepatitis Data From AASLD 2022*

Read expert faculty members’ summaries of HBV, HDV, and HCV studies, including data on HBV therapy during pregnancy, HBV therapeutic vaccines and progress toward an HBV cure, HDV clinical impact and phase III clinical trial updates, and HCV implementation science and current status of the cascade of care.

Nancy Reau, MD Stefan Zeuzem, MD Released: November 16, 2022

One of the biggest messages from AASLD 2022 was that we still have a lot of work to do. Between the pandemic and propagation of unhealthy behaviors, there’s still an incredible burden of liver disease, and viral hepatitis continues to contribute to it.

Nancy Reau, MD Released: December 2, 2022

There were many exciting developments in viral hepatitis presented at AASLD 2022, which makes me look forward to guideline updates to reflect evolving screening and therapeutic recommendations for HBV, HCV, and HDV.

Stefan Zeuzem, MD Released: December 5, 2022

Listen to expert insights on updates and new viral hepatitis data from AASLD 2022, including data on HBV therapy during pregnancy, HBV therapeutic vaccines and progress toward HBV cure, HDV clinical impact and phase III clinical trial updates, and HCV implementation science and HCC risk reduction with use of DAAs.

Stefan Zeuzem, MD Released: December 7, 2022

Listen to expert insights on updates and new viral hepatitis data from AASLD 2022, including data on HBV therapy during pregnancy, HBV therapeutic vaccines and progress toward HBV cure, HDV clinical impact and phase III clinical trial updates, and HCV implementation science and HCC risk reduction with use of DAAs.

Nancy Reau, MD Released: December 8, 2022

Listen to expert insights from Stefan Zeuzem, MD, on updates and new viral hepatitis data from AASLD 2022, including data on HBV therapy during pregnancy, HBV therapeutic vaccines and progress toward HBV cure, HDV clinical impact and phase III clinical trial updates, and HCV implementation science and HCC risk reduction with use of DAAs.

Stefan Zeuzem, MD Released: December 6, 2022

Listen to expert insights from Nancy Reau, MD, on practice-changing viral hepatitis data from AASLD 2022, including HBV therapeutics in the pipeline, HCV management strategies, HDV screening and care linkage, fatty liver disease in patients with viral hepatitis, and the role of statins in patients with liver disease.

Nancy Reau, MD Released: December 6, 2022